

Reference Data

1st Quarter - Fiscal Year 2017
(April 1, 2017 to June 30, 2017)

Consolidated Earnings

• Consolidated Financial Data	P 1
• Consolidated Balance Sheets	P 2
• Consolidated P/L Statement	P 3
• Consolidated Sales Breakdown by Segment/Category	P 4
• Consolidated Operating Income by Segment	P 4
• Consolidated Sales - Leading Brands of Self-Medication Operations	P 5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	P 6
• Capital Expenditure	P 7
• Depreciation and Amortization	P 7
• R&D Expenses	P 7
• Results of Major Consolidated Subsidiaries	
♦ Taisho Pharmaceutical	P 8
♦ Taisho Toyama Pharmaceutical	P 8
♦ Biofermin Pharmaceutical	P 8
• Major Subsidiaries and Affiliates	P 9
• Prescription Pharmaceutical Operations: New Drug Development-Taisho Pharmaceutical	P10
• Launch of New Products	P12

Consolidated Financial Data

(Millions of yen)

	March 2017(FY2016)				March 2018(FY2017)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Net sales	69,431	141,007	216,431	279,773	68,532	137,500	279,000
(YOY%)	(+0.3%)	(-3.4%)	(-3.8%)	(-3.6%)	(-1.3%)	(-2.5%)	(-0.3%)
Self-Medication operations	43,012	90,457	138,160	179,992	44,823	89,300	181,300
Prescription Pharmaceutical operations	26,418	50,550	78,270	99,781	23,709	48,200	97,700
Gross profit*	44,409	90,333	138,365	178,226	44,300	88,400	180,900
Selling, general and administrative expenses	35,302	73,678	111,804	146,260	37,358	76,900	152,400
Research and development expenses	5,050	10,496	15,519	21,260	5,291	12,400	24,000
(% Sales)	(7.3%)	(7.4%)	(7.2%)	(7.6%)	(7.7%)	(9.0%)	(8.6%)
Advertising expenses	5,013	10,595	17,880	22,087	5,975	11,400	23,200
Sales promotion expenses	7,082	15,069	23,338	30,079	7,307	15,400	31,100
Personnel expenses	9,090	18,078	27,034	35,845	8,874	18,100	36,300
Operating income	9,106	16,655	26,560	31,966	6,941	11,500	28,500
(YOY%)	(+74.0%)	(+19.6%)	(+16.9%)	(+10.7%)	(-23.8%)	(-31.0%)	(-10.8%)
Ordinary income	10,422	19,129	31,376	38,036	8,796	14,500	34,500
(YOY%)	(+39.1%)	(+8.2%)	(+7.8%)	(+3.4%)	(-15.6%)	(-24.2%)	(-9.3%)
Profit attributable to owners of parent	6,945	13,499	23,670	28,781	5,534	10,500	24,000
(YOY%)	(+48.2%)	(+19.7%)	(+26.5%)	(+28.1%)	(-20.3%)	(-22.2%)	(-16.6%)
Comprehensive income	3,455	5,317	18,994	30,184	10,303	-	-
(YOY%)	(-47.7%)	(-30.2%)	(-4.7%)	(+233.2%)	(+198.2%)	-	-
Basic EPS (yen)	86.92	168.93	296.21	360.18	69.27	131.41	300.38
Diluted EPS (yen)	86.86	168.82	296.01	359.92	69.21	131.32	300.17
BPS (yen)	7,857.63	7,876.45	7,990.93	8,127.87	8,189.49	8,200.44	8,319.97
Dividend per share (yen)	-	50.00	-	110.00	-	50.00	110.00
Payout ratio	-	-	-	30.5%	-	-	36.6%
Capital expenditure	2,453	4,262	5,040	7,011	685	2,260	5,790
Depreciation and amortization	2,529	5,099	7,732	10,423	2,474	5,000	10,300
Total assets	751,353	752,705	762,998	771,222	779,358	777,000	787,000
Shareholders' equity	642,439	644,393	653,919	665,088	669,809	671,000	681,000
Return on equity (%)**	-	-	-	4.5%	-	-	3.7%
Return on assets (%)**	-	-	-	3.8%	-	-	3.1%
Equity ratio (%)	83.6%	83.6%	83.7%	84.2%	84.0%	84.3%	84.5%
Overseas sales	6,836	13,769	20,361	27,529	8,283	14,310	29,520
Overseas sales ratio (% of total sales)	9.9%	9.8%	9.4%	9.8%	12.1%	10.4%	10.6%
Number of employees	6,596	6,515	6,486	6,461	6,525	-	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

<Reference>

• E = Estimates

• The 2Q forecasts (previous) for the fiscal year ending March 31, 2018 were announced on May 15, 2017.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2016		End of FY2017/1Q		change	
	(March 31, 16)	% total	(Jun. 30, 16)	% total		
(Assets)						
I Current assets:	308,946	40.1%	312,098	40.0%	+3,151	
Cash and deposits	201,275		202,113		+837	
Notes and accounts receivable-trade	69,535		69,536		+0	
Inventories	27,501		27,683		+182	
Deferred tax assets	5,819		6,617		+797	
Other	4,814		6,147		+1,333	
II Fixed assets:	462,276	59.9%	467,260	60.0%	+4,984	
(1) Tangible fixed assets:	97,282	(12.6%)	95,590	(12.3%)	-1,692	
Buildings and structures	49,957		49,174		-782	
Machinery, equipment and vehicles	6,372		6,014		-357	
Land	37,457		37,033		-423	
Other	3,496		3,368		-127	
(2) Intangible fixed assets:	34,372	(4.5%)	33,120	(4.2%)	-1,252	
Goodwill	16,768		15,988		-780	
Sales rights	4,068		3,731		-336	
Trademarks	9,966		9,668		-297	
Software	3,046		3,066		+20	
Other	523		665		+142	
(3) Investments and other assets:	330,620	(42.9%)	338,549	(43.4%)	+7,928	
Investment securities	252,459		261,938		+9,478	Gain/loss on valuation +7,466, Bond purchases +2,093
Shares of subsidiaries and affiliates	67,550		66,301		-1,248	
Net defined benefit assets	2,496		2,559		+63	
Deferred tax assets	6,783		6,377		-406	
Other	1,330		1,372		+41	
Total assets	771,222	100.0%	779,358	100.0%	+8,136	
(Liabilities)						
I Current liabilities:	58,097	7.5%	59,720	7.7%	+1,622	
Notes and accounts payable-trade	23,327		21,108		-2,218	
Accounts payable	13,047		13,669		+622	
Accrued income tax	5,774		4,460		-1,314	
Provision for bonuses	3,854		2,019		-1,834	
Other	12,094		18,462		+6,367	
II Long-term liabilities:	48,036	6.2%	49,828	6.4%	+1,791	
Net defined benefit liabilities	23,505		23,484		-20	
Deferred taxes liabilities	16,130		18,082		+1,951	
Other	8,400		8,261		-138	
Total liabilities	106,134	13.8%	109,549	14.1%	+3,414	
(Net assets)						
I Shareholders' equity	621,583	80.6%	622,311	79.8%	+728	
Common stock	30,000	3.9%	30,000	3.8%	-	
Capital surplus	15,272	2.0%	15,272	2.0%	-0	
Retained earnings	644,038	83.5%	644,775	82.7%	+736	Profit attributable to owners of parent +5,543 Dividend on retained earnings -4,798
Treasury stock	-67,727	-8.8%	-67,735	-8.7%	-7	
II Accumulated other comprehensive income	27,875	3.6%	32,066	4.1%	+4,190	
Valuation difference on securities	36,234	4.7%	41,562	5.3%	+5,328	
Deferred gains or losses on hedges	0	0.0%	0	0.0%	-0	
Foreign currency translation adjustment	-2,195	-0.3%	-3,467	-0.4%	-1,271	
Remeasurements of defined benefit plans	-6,162	-0.8%	-6,029	-0.8%	+133	
III Subscription rights to shares	478	0.1%	471	0.1%	-7	
IV Non-controlling interests	15,150	2.0%	14,960	1.9%	-190	
Total net assets	665,088	86.2%	669,809	85.9%	+4,721	
Total liabilities and net assets	771,222	100.0%	779,358	100.0%	+8,136	

Consolidated P/L Statement

(Millions of yen)

	FY2016		FY2017		YOY change	
	1Q	% total	1Q	% total		
Net sales	69,431	100.0%	68,532	100.0%	-899	
Cost of sales	25,032	36.1%	24,232	35.4%	-800	
Gross profit on sales	44,398	63.9%	44,299	64.6%	-99	
Provision for sales returns	-10		-0		+9	
Gross profit	44,409	64.0%	44,300	64.6%	-108	
Selling, general and administrative expenses	35,302	50.8%	37,358	54.5%	+2,056	
Research and development expenses	5,050		5,291		+241	
Advertising expenses	5,013		5,975		+961	
Sales promotion expenses	7,082		7,307		+224	
Personnel expenses	9,090		8,874		-216	
Other	9,065		9,911		+845	
Operating income	9,106	13.1%	6,941	10.1%	-2,165	
Non-operating income	2,346	3.4%	2,241	3.3%	-105	
Non-operating expenses	1,031	1.5%	386	0.6%	-645	FY2016: Foreign exchange losses 776
Ordinary income	10,422	15.0%	8,796	12.8%	-1,625	
Extraordinary gains	10	0.0%	742	1.1%	+732	Gains from sale of fixed assets 742
Extraordinary losses	92	0.1%	9	0.0%	-83	
Income before income taxes and minority interests	10,339	14.9%	9,529	13.9%	-810	
Income taxes	2,846	4.1%	3,478	5.1%	+631	
Profit	7,492	10.8%	6,050	8.8%	-1,442	
Profit attributable to non-controlling interests	547	0.8%	515	0.8%	-31	
Profit attributable to owners of parent	6,945	10.0%	5,534	8.1%	-1,410	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2017(FY2016)				March 2018(FY2017)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Self-Medication operations (YOY%)	43,012 (-1.4%)	90,457 (-1.8%)	138,160 (-0.4%)	179,992 (-0.4%)	44,823 (+4.2%)	89,300 (-1.3%)	181,300 (+0.7%)
Japan	35,560	75,344	115,723	149,733	35,949	73,600	149,300
Overseas	6,832	13,757	20,347	27,507	8,281	14,300	29,500
Other	620	1,355	2,090	2,751	592	1,400	2,500
Prescription Pharmaceutical operations (YOY%)	26,418 (+3.2%)	50,550 (-6.2%)	78,270 (-9.2%)	99,781 (-8.8%)	23,709 (-10.3%)	48,200 (-4.7%)	97,700 (-2.1%)
Ethical drugs	24,562	48,140	75,451	96,126	22,732	46,800	95,100
Other	1,856	2,410	2,819	3,655	976	1,400	2,600
Total	69,431	141,007	216,431	279,773	68,532	137,500	279,000

Consolidated Operating Income by Segment

(Millions of yen)

	March 2017(FY2015)				March 2017(FY2016)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E(new) (4-9)	Full year E
Self-Medication operations (YOY%)	7,022 (+15.7%)	15,203 (+4.6%)	22,744 (+7.8%)	30,106 (+6.0%)	5,843 (-16.8%)	11,700 (-23.0%)	26,000 (-13.6%)
Prescription Pharmaceutical operations (YOY%)	2,496 (-)	2,272 (-)	4,981 (+92.2%)	3,352 (+90.9%)	1,414 (-43.3%)	500 (-78.0%)	3,900 (+16.3%)
Other* (YOY%)	-412 (-)	-820 (-)	-1,165 (-)	-1,492 (-)	-316 (-)	-700 (-)	-1,400 (-)
Total	9,106	16,655	26,560	31,966	6,941	11,500	28,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2017(FY2016)				March 2018(FY2017)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Japan	35.6	75.3	115.7	149.7	35.9	+1.1%	73.6	149.3	-0.3%
Lipovitan series	15.6	33.0	47.4	58.5	14.6	-6.3%	31.4	56.8	-2.9%
Pabron series	4.3	10.2	18.8	26.3	4.6	+7.9%	10.5	26.9	+2.2%
RiUP series	3.8	7.9	12.3	16.1	3.7	-1.9%	7.7	15.9	-1.0%
VICKS series	0.5	1.5	2.9	3.6	0.5	-7.9%	1.5	4.2	+15.0%
Gastrointestinal treatment series	0.9	1.8	3.0	4.0	0.9	+1.7%	1.8	3.9	-2.3%
Livita series	0.9	1.9	2.9	3.8	0.9	-4.5%	1.7	3.6	-5.6%
NARON series	0.9	1.7	2.6	3.4	0.7	-14.6%	1.6	3.5	+4.1%
Colac series	0.8	1.6	2.5	3.3	0.9	+8.7%	1.6	3.3	+0.3%
Biofermin series	2.0	4.2	6.7	8.8	2.4	+17.6%	3.6	7.9	-10.6%
Overseas	6.8	13.8	20.3	27.5	8.3	+21.2%	14.3	29.5	+7.2%
Energy drinks	2.5	4.9	7.2	9.4	2.8	+12.5%	5.0	9.9	+5.6%
OTC drugs	4.2	8.5	12.6	17.2	5.1	+20.6%	8.7	18.3	+6.6%
Others	0.6	1.4	2.1	2.8	0.6	-4.5%	1.4	2.5	-9.1%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2017(FY2016)				March 2018(FY2017)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Lipovitan series	15.6	33.0	47.4	58.5	14.6	-6.3%	31.4	56.8	-2.9%
Lipovitan D	10.2	21.4	30.5	37.2	9.5	-6.6%	20.4	36.1	-3.1%
Others	5.4	11.6	17.0	21.3	5.1	-5.7%	11.0	20.7	-2.5%
(100mL other Lipovitans)	3.5	7.4	10.8	13.5	3.4	-3.1%	7.1	13.2	-2.3%
(50mL other Lipovitans)	1.9	4.2	6.1	7.7	1.7	-10.4%	3.9	7.5	-2.8%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2017(FY2016)				March 2018(FY2017)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Edirol	5.8	11.3	17.5	22.6	6.2	+8.0%	12.3	25.0	+10.6%
ZOSYN	4.2	8.3	12.7	15.5	2.8	-34.3%	5.6	9.5	-38.8%
Clarith	2.2	4.0	7.2	9.3	1.9	-14.7%	3.7	8.5	-8.8%
Bonviva	1.7	3.1	4.6	5.9	1.6	-5.8%	3.4	7.1	+20.1%
Palux	1.5	2.8	4.2	5.4	1.3	-13.0%	2.5	4.8	-10.4%
Lusefi	0.5	1.5	2.1	2.9	1.2	+157.9%	2.1	4.8	+67.1%
OZEX	1.1	2.2	4.1	4.9	0.9	-19.1%	2.1	4.7	-4.3%
Geninax	1.1	2.7	3.9	5.2	0.2	-77.8%	2.0	4.5	-13.5%
Biofermin	1.0	2.0	3.0	3.9	1.2	+11.8%	2.1	4.2	+6.9%
LOQOA	0.3	0.5	1.1	1.8	0.8	+199.5%	1.6	3.6	+98.5%

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2017(FY2016)				March 2018(FY2017)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total capital expenditure	2,453	4,262	5,040	7,011	685	2,260	5,790
Taisho Pharmaceutical	2,268	3,668	4,343	6,013	539	1,860	4,590
Production department	28	387	586	1,104	195	440	1,270
Research department	134	381	509	893	209	450	1,050
Head Office and the others	2,105	2,899	3,246	4,015	134	970	2,270
Other subsidiaries	185	593	696	998	145	400	1,200

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2017(FY2016)				March 2018(FY2017)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Depreciation and amortization	2,529	5,099	7,732	10,423	2,474	5,000	10,300
Cost of sales	851	1,670	2,524	3,411	751	1,500	3,200
SGA expenses	1,678	3,429	5,207	7,011	1,722	3,500	7,100

Consolidated: R&D Expenses

(Millions of yen)

	March 2017(FY2016)				March 2018(FY2017)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total R&D expenses	5,050	10,496	15,519	21,260	5,291	12,400	24,000
Self-Medication operations	1,320	2,825	4,104	5,497	1,495	3,400	6,400
Prescription Pharmaceutical operations	3,730	7,670	11,415	15,763	3,796	9,000	17,600

Results of Major Consolidated Subsidiaries

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2017(FY2016)				March 2018(FY2017)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	49.2	101.6	156.4	203.1	49.3	+0.2%	99.8	204.3	+0.6%
Self-Medication	35.9	76.2	117.2	152.0	36.4	+1.4%	74.4	150.8	-0.8%
Prescription Pharmaceutical	13.4	25.4	39.2	51.1	12.9	-3.2%	25.4	53.5	+4.6%
Operating income	5.9	11.1	17.9	23.1	3.8	-35.1%	7.1	19.4	-15.9%
Ordinary income	6.6	13.8	20.9	26.5	7.9	+19.2%	12.7	25.5	-3.6%
Profit	5.2	10.5	16.0	20.1	6.1	+17.5%	10.8	20.1	+0.5%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical

(Billions of Yen)

	March 2017(FY2016)				March 2018(FY2017)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	24.6	48.1	75.5	96.1	22.7	-7.5%	46.8	95.1	-1.1%
Operating income	1.4	2.0	2.9	2.0	0.4	-74.4%	1.1	2.3	+11.6%
Ordinary income	1.4	2.0	3.0	2.1	0.4	-74.0%	1.1	2.3	+8.7%
Profit	0.9	1.3	1.9	1.3	0.2	-74.2%	0.7	1.4	+13.0%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical are included in the consolidated results of Prescription Pharmaceutical operations.

Sales and earnings of Biofermin Pharmaceutical

(Billions of Yen)

	March 2017(FY2016)				March 2018(FY2017)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	2.6	5.1	8.1	10.6	3.0	+17.6%	5.7	10.6	+0.0%
Self-Medication	1.7	3.4	5.5	7.3	2.0	+13.9%	4.0	7.2	-1.2%
Prescription Pharmaceutical	0.8	1.7	2.6	3.4	1.1	+25.3%	1.7	3.4	+2.6%
Operating income	0.7	1.3	2.3	2.7	1.1	+53.6%	1.6	2.7	+0.1%
Ordinary income	0.8	1.3	2.3	2.7	1.1	+51.3%	1.6	2.7	+0.8%
Profit	0.5	0.9	1.6	1.9	0.8	+51.2%	1.1	1.9	+0.1%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of June 30, 2017)

Company	Address	Capital	Business	Ownership [*]
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 29,804,450	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	64.0
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70.3
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.0
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
(2) Equity accounting method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000,000	PD	34.0
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 871,643,300	SMG	24.4

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of Aug 2, 2017

In Japan

Phase 2

TS-091 (Oral)

< Application > Central disorders of hypersomnolence
< Development > In-house

TS-152 (Injection)

< Application > Rheumatoid arthritis
< Development > In-license (Licensor: Ablynx)
< Description > Anti-TNF(Tumor Necrosis Factor)- α antibody
< Remarks > Generic name: Ozoralizumab

TS-141 (Oral)

< Application > Childhood Attention-Deficit/Hyperactivity Disorder
< Development > In-house

TS-133 (Topical)

< Application > Alopecia
< Development > In-house

TS-142 (Oral)

< Application > Insomnia
< Development > In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of Aug 2, 2017

Overseas

Phase 2

TS-121 (Oral)

< Application > Depression

< Development > In-house

Phase 1

TS-071 (Oral)

< Target disease > Type 2 diabetes

< In-house/Licensed-in > In-house

< Description > Sodium-glucose cotransporter 2 (SGLT2) inhibitor

< Remarks > Generic name: Luseogliflozin Hydrate

In Japan: Launched on May 23, 2014 (Product name: Lusefi)

TS-091 (Oral)

< Target disease > Central disorders of hypersomnolence

< In-house/Licensed-in > In-house

TS-134 (Oral)

< Target disease > Schizophrenia

< In-house/Licensed-in > In-house

Launch of New Products

As of Aug 2, 2017

New Products Since FY2016 Earnings Announcement (May 15, 2017)

Self-Medication Operations

Lipovitan D limited-edition Dragon Ball bottle

< Description > These Lipovitan D limited-edition bottles feature designs based on characters from the popular anime series Dragon Ball.

Sold in limited quantities at major convenience stores nationwide, as well as through our online store, Taisho Pharmaceutical Direct.

Effective for alleviating physical fatigue, nutritional support and fortification during and after illness, and for infirmity and other related conditions.

< Launch > Since Aug 2017
